Takeda Recalls Natpara (parathyroid hormone) Injection Formulation in the US

 Takeda Recalls Natpara (parathyroid hormone) Injection Formulation in the US

Takeda Recalls Natpara (parathyroid hormone) Injection Formulation in the US

Shots:

  • Takeda is issuing a recall for all doses of Natpara for injection (25/50/75/100 mcg) in the US after the discussion with US FDA due to the potential for rubber particulate instigating from the rubber septum of the NATPARA cartridge
  • Takeda is advising patients to consult with their healthcare providers about the discontinuation of Natpara treatment as it may lead to severe hypocalcemia resulting in serious health consequences
  • Natpara is a recombinant human protein with 84 amino acid sequence of endogenous parathyroid hormone. Healthcare providers can contact Takeda for queries related to recall at +1-800-828-2088 & select Option 2 and patients can contact OnePath at +1-866-888-0660

Click here to­ read full press release/ article | Ref: Takeda | Image: Yahoo Finance

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post